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Abstract
Life expectancy in multiple myeloma has significantly increased. However, a high incidence of chemotherapy induced
peripheral neuropathy (CIPN) can negatively influence quality of life during this period. This study applied functional
magnetic resonance imaging (fMRI) to compare areas associated with central pain processing in patients with multiple
myeloma who had chemotherapy induced peripheral neuropathy (MM-CIPN) with those from healthy volunteers (HV).
Twenty-four participants (n = 12 MM-CIPN, n = 12 HV) underwent Blood Oxygen Level-Dependent (BOLD) fMRI at 3T whilst
noxious heat-pain stimuli were applied to the foot and then thigh. Patients with MM-CIPN demonstrated greater activation
during painful stimulation in the precuneus compared to HV (p = 0.014, FWE-corrected). Patients with MM-CIPN exhibited
hypo-activation of the right superior frontal gyrus compared to HV (p = 0.031, FWE-corrected). Significant positive
correlation existed between the total neuropathy score (reduced version) and activation in the frontal operculum (close to
insular cortex) during foot stimulation in patients with MM-CIPN (p = 0.03, FWE-corrected; adjusted R2 = 0.87). Painful stimuli
delivered to MM-CIPN patients evoke differential activation of distinct cortical regions, reflecting a unique pattern of central
pain processing compared with healthy volunteers. This characteristic activation pattern associated with pain furthers the
understanding of the pathophysiology of painful chemotherapy induced peripheral neuropathy. Functional MRI provides a
tool for monitoring cerebral changes during anti-cancer and analgesic treatment.
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Introduction
Modern cancer treatments may be associated with chemother-
apy-induced peripheral neuropathy (CIPN), a potentially devas-
tating side effect. Multiple myeloma (MM) is a haematological
malignancy that has a particularly high incidence of CIPN
following the administration of thalidomide, bortezomib or
vincristine [1,2]. Neuropathy due to chemotherapy in myeloma
may be painful and disabling. Moreover CIPN development may
necessitate chemotherapy dose reduction or cessation [3,4].
Although some resolution of CIPN is possible, there is increasing
recognition of the progressive chronicity of painful neuropathy in
many patients. In addition, this frequently leads to the need for
long-term administration of analgesic drugs with their attendant
side effect profiles. Even with current analgesics, therapeutic
response is often very poor [5]. Moreover, early diagnosis and
objective assessment of CIPN and its symptomatic treatments are
unsatisfactory. Overall, CIPN can result in reduced quality of life
and impact on survival. This runs counter to the recent
achievements linked to improved life expectancy from modern
anti-cancer drugs [6].
Chemotherapy-induced peripheral neuropathy is thought to be
caused by drug-induced damage to components of the peripheral
nervous system (PNS) [7]. Neuropathy associated with thalidomide
is thought to arise from Wallerian degeneration of the peripheral
nerve fibres contributing to the development of pain via
production of cytokines such as tumour necrosis factor-a and
nerve growth factors [8]. Bortezomib-induced neuropathy is
associated with deficits in Ab, Ad and C primary afferent fibres.
There could potentially be a dysregulation of the neurotrophic
factors since bortezomib inhibits the activation of the transcription
factor, nuclear factor-kappa B and blocks the transcription of the
trophic nerve growth factor [2]. Vincristine acts by binding on
intracellular tubulin, which interferes with axonal transport. It is
thought that it induces alterations in the cellular microtubule
structure in the PNS and this might be a mechanistic link to
neuropathic development [9,10]. Neuropathic symptoms are
usually more common and severe in the lower extremities than
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in the upper extremities as the longest nerves are thought to be the
first affected. Sensory changes affecting the toes, finally progress
proximally to the ankles in a glove and stocking distribution [11].
Structural damage to the PNS results in abnormal somatosensory
processing in the central and peripheral nervous systems [12].
Most of the current ideas regarding the pathophysiology of
neuropathic pain originated from experimental work in animal
models indicating peripheral and spinal cord reorganization of
nociceptive pathways [13]. Animal models of neuropathic injuries
that result in persistent pain suggest that peripheral and spinal
cord impulses transmitting nociceptive signals towards the cortex
undergo remarkable reorganization [14,15]. Although peripheral
abnormalities are prominent, the central nervous system (CNS)
appears to show concomitant involvement. Abnormalities in pain
processing as shown on neuroimaging rather than just damage or
inflammation to the peripheral nerves, seem to play an important
part in chronic painful conditions such as trigeminal neuralgia,
post-herpetic neuralgia, chronic low back pain and diabetic
neuropathy [16–20]. Areas of brain activation that have been
reported in chronic pain include the frontal lobe, insular cortex,
somatosensory cortex, thalamus, periaquedactal grey and precu-
neus [21–23].
Our understanding of the pathological mechanisms underlying
CIPN and identification of possible future treatment target areas
for this debilitating complication may be significantly enhanced by
the application of functional magnetic resonance imaging (fMRI).
To our knowledge, to date there have been no reported fMRI
studies in patients with multiple myeloma who have developed
treatment emergent CIPN, that have attempted to document pain
processing within the brain.
The aim of this work was to assess any alterations to the brain’s
cortical and sub-cortical pain matrix in MM-CIPN due to factors
including: chemotherapy, chronicity of painful neuropathy and
psychological adaptation. In light of previous pain-related
functional studies, we hypothesised that regions such as the frontal
cortex, insula, and postcentral gyrus, known to be involved in
cognition and emotion processing and sensory perception, would
be modulated by the presence of post-chemotherapeutic chronic
neuropathy. To test this hypothesis, we used Blood Oxygenation
Level Dependent (BOLD) fMRI to study central pain processing
during noxious thermal stimulation in patients with MM who had
already developed CIPN and to compare these findings to those
from healthy volunteers (HV).
Material and Methods
Ethics statement
The study was granted ethical approval by the Sheffield
Research Ethics Committee (REC no: 08/H1308/276) and the
participants’ written informed consent was obtained in accordance
with the Declaration of Helsinki.
Subjects
The study sample comprised MM-CIPN patients and healthy
volunteers. Myeloma patients had been treated with at least one of
the anti-myeloma therapies commonly associated with CIPN (i.e;
thalidomide, bortezomib or vincristine) and had experienced
neuropathic pain of at least six months duration. Exclusion criteria
included history of any major neurological or psychiatric disorder,
contraindications to MRI, claustrophobia, left hand dominance,
and neuropathy caused by other medical conditions. In addition,
MM-CIPN patients who could not discontinue their tricyclics,
noradrenaline reuptake inhibitors and/or calcium channel blocker
analgesic medication for at least 48 hours prior to scanning were
excluded. Patients who were on a long term, stable dose of opioids
were included. Subjects did not receive any financial incentive for
their participation. For each subject, demographic data collection,
neuropathy assessment, chronic pain assessment and MR imaging
were all undertaken on the same day.
Neuropathy assessment
All subjects underwent detailed clinical and neurophysiological
assessments to diagnose and quantify the presence of neuropathy.
This included a detailed clinical history and examination,
quantitative sensory testing and peripheral nerve conduction
assessment. Sensory testing using Computer Assisted Sensory
Evaluation IV equipment comprised vibration perception, cooling
and heating detection threshold of the right foot (CASE IV) (W.R.
Electronics, Stillwater, MN, USA). Peripheral nerve conduction
studies were performed at a stable skin temperature of 31uC
(Medelec electrophysiological system, Synergy Oxford Instru-
ments, Oxford, U.K.). A total neuropathy score reduced version
(TNS-reduced version) was used, as has previously been used to
stage neuropathy in MM patients [24]. This score evaluates motor
and sensory symptoms and signs, quantitates pinprick and
vibration perception threshold, and includes neurophysiological
examination of one motor and one sensory nerve in the leg. The
TNS-reduced version composite score ranges from 0 to 32; and
the presence of neuropathy was defined as having a TNS-reduced
version score .2.
Chronic pain assessment
To cover the psychosocial consequences of the pain experienced
by the MM-CIPN patients, additional assessment tools were used.
The chronic pain acceptance questionnaire (CPAQ) provides
information on how chronic pain affects patients and is rated on a
0 (never true) to 6 (always true) scale [25]. The CPAQ total score
ranges from 0 to 120, with a higher score indicating higher
acceptance of pain. It shows the level of acceptance of chronic pain
and focuses on participation in activities, the pursuit of personally
relevant goals and the relative absence of attempts to control or
avoid pain.
The pain catastrophizing scale (PCS) is a 13-item self-report test
whose items are rated on a 5-point Likert-type scale. Ratings range
from 0 (not at all) to 4 (always) representing the degree to which
the subject experienced each of 13 thoughts or feelings when in
pain [26]. The PCS total scores range from 0–52. The items fall
within three different categories to assess negative thinking styles
related to pain: rumination, magnification, and helplessness.
Heat-pain stimulation protocol
All heat-pain stimulation was applied to the right hand side of
the body for each participant. The experimental thermal stimulus
was delivered using a computer-controlled, MR-compatible,
contact heat evoked potential device (CHEPS), which rapidly
delivers heat with controllable temperatures (Medoc Pathway
System, Medoc Ltd, Ramat Yishai, Israel). The foot was chosen as
the primary stimulation area as this is the anatomical location
where patients with CIPN develop pain-related symptomatology.
The thigh was the secondary stimulation site and it was chosen as
a potential control site, not being associated with neuropathic
pain.
Prior to each subject entering the MR scanner, a simple heat
pain-rating test was performed to determine the temperature
threshold necessary to elicit a score of at least 7 on an 11-point
numeric rating scale (with reference to a 0–10 point numeric
rating scale; where 0 represented no pain and 10 represented the
most extreme pain). This was performed separately for stimulation
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at both foot and thigh. The pain rating protocol started with a
temperature application of 44.9uC at the foot and 42.9uC at the
thigh. At these and subsequent temperature iterations, each
subject reported their subjective pain status. The temperature was
increased or decreased by 0.5–2uC until a pain score of 7/10 was
identified. The maximum temperature at either site was set at
47.9uC. Thermal stimulation has been consistently used in other
fMRI studies and has been shown to be an effective way to
describe brain activity maps in response to thermal pain [27].
Each fMRI run comprised the presentation of 7 blocks of heat-
pain stimuli (duration 30 seconds), at the pre-determined 7/10
pain-inducing temperature, interspersed with 7 blocks at a baseline
temperature of 32uC (each baseline block duration was pseudo-
randomised to 55, 60 or 65 seconds). Timing of the applied
temperature protocol was controlled by the pre-programmed
thermode-device computer. At the end of the imaging session, all
participants rated their overall pain when the heat-pain stimulus
was delivered to the foot and to the thigh. This was done by asking
subjects to verbally rate the intensity of the pain on a numerical
scale from zero (no pain) to ten (maximum imaginable pain).
Scanning protocol and fMRI acquisition
A fixed scanning protocol was used for every subject. Magnetic
Resonance data were acquired at 3 Tesla (Achieva 3.0T, Philips
Healthcare, Best, Holland). The scanning protocol included
acquisition of standard T1-weighted, 3-dimensional and T2-
weighted, 2-dimensional anatomical images prior to two fMRI
runs. The fMRI datasets were acquired using a single-shot, T2*-
weighted, gradient-recalled, echo planar imaging (EPI) sequence
(Time to echo (TE) = 35 ms; Time to repeat (TR) = 3000 ms;
SENSE encoding factor = 1.5). For each dataset, 35 contiguous
transaxial slices of 4 mm thickness, with an in-plane resolution of
1.8 mm61.8 mm were acquired at each imaging time-point or
temporal dynamic (phase encoding in the anterior-posterior
direction). Synchronicity was maintained between the scanner
fMRI acquisition and the thermode-device PC control.
fMRI analysis
Imaging data analysis was carried out using statistical paramet-
ric mapping software (SPM5: www.fil.ion.ucl.ac.uk/spm). Blood
oxygen level dependent response was modelled using a box-car
waveform convolved with a canonical haemodynamic response
function. Following spatial pre-processing, which included re-
alignment, spatial normalisation and spatial smoothing, images
were analysed using the General Linear Model. First-level
functional images were produced comparing the BOLD response
under the heat pain condition with the BOLD signal obtained at
the baseline temperature. These contrast estimate maps were
produced for every functional run at each of the two anatomical
stimulation sites (foot and thigh) for each subject. Therefore, the
first-level analysis yielded 2 contrast images per subject, comparing
BOLD response under the heat-pain condition with baseline at (i)
foot and (ii) thigh stimulation sites.
The resultant first-level contrast images were combined at the
group level in a flexible factorial model with factors of subject,
group (MM-CIPN and healthy volunteers) and site (foot and
thigh). This appropriately modelled the independence of observa-
tions between subjects and groups, and the inequality of variance
across all factors.
Within-group images of all pain (foot and thigh) response versus
baseline were produced for each of the MM-CIPN and healthy
volunteer groups. The statistical threshold for reporting within-
group pain contrast activation was p,0.05, family-wise error
(FWE) corrected across the whole spatial brain volume.
A functional anatomical mask of voxels activated in response to
all heat-pain stimuli (compared with baseline) in both groups of
Table 1. Baseline characteristics (median [IQR]) of the subjects recruited.
Multiple Myeloma patients Healthy Volunteers p-value
Group Size 12 12 0






Duration of MM (Years) 4.1 [2.0–7.7] Not applicable 0
Duration of neuropathic pain (Years) 2 [0.9–3.2] Not applicable 0
doi:10.1371/journal.pone.0096474.t001
Table 2. Group median [IQR] temperature for pain stimulation and pain rating.
Healthy Volunteers MM patients p-value
Foot stimulation
Temperature (6C) 46.7 [45.5–47.8] 47.2 [46.6–47.9] 0.23
Pre-scan pain rating (0–10) 7.5 [6.6–8.0] 7.0 [7.0–8.0] 0.74
Post-scan pain rating (0–10) 7.7 [6.6–8.7] 7.7 [7.0–8.0] 0.95
Thigh stimulation
Temperature (6C) 45.9 [45.6–47.9] 46.7 [45.5–47.9] 0.88
Pre-scan pain rating (0–10) 7.7 [5.9–8.0] 8.0 [7.6–8.0] 0.28
Post-scan pain rating (0–10) 8.0 [6.2–8.9] 8.0 [8.0–9.0] 0.29
doi:10.1371/journal.pone.0096474.t002
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subjects (MM-CIPN and healthy volunteers) was created at a
voxel-level statistical threshold p,0.001, uncorrected. This
masking approach was used in order to reflect any variance in
functional-anatomical location resulting from disease-specific
pathogenesis. The mask was used as a volume-of-interest for
correction for multiple comparisons in subsequent between-group
contrasts.
The statistical threshold for reporting between-group differences
in pain-evoked activation was p,0.05 FWE corrected (voxel-level)
or p,0.05 corrected for extent of activation (cluster level) in either
the whole brain volume or functionally defined region-of-interest
(above). All activation results were displayed in the anatomical
space as defined by the Montreal Neurological Institute (MNI)
with stereotactic co-ordinates converted to the standard space of
Talairach and Tournoux for the purposes of neuroanatomical
labelling [28,29].
Behavioural data statistical analysis
Quantitative data were analysed using PASW Statistics version
18 [30]. Because of the asymmetric distribution of the cohort, a
non-parametric (Mann-Whitney U test) was used for group
comparisons. A linear regression analysis of fMRI signal response
to heat-pain stimulation at the foot (i.e., neuropathic site) within
the MM-CIPN patient group with TNS-reduced version and with
the CPAQ and the PCS questionnaire scores was performed.
Results
Baseline characteristics
Twenty-four subjects were recruited (table 1): twelve MM-CIPN
patients (8 males) and 12 healthy volunteers (6 males). The median
age of the myeloma group was 63 years whilst that of the healthy
volunteers was 53 years. Myeloma patients had the disease for a
median [inter-quartile range (IQR)] of 4 [2–7.7] years and had
neuropathic pain for a median of 2 [0.9–3.2] years. The anti-
myeloma therapy that these patients received, which are known to
cause peripheral neuropathy, varied between patients: n = 5 (42%)
vincristine, n = 9 (75%) thalidomide and n = 8 (67%) bortezomib.
All participants completed the study and none were excluded.
Neurological assessment and pain stimulation
Neurophysiological tests showed abnormality in each MM-
CIPN subject indicative of peripheral neuropathy in the feet. The
median [IQR] of the TNS-reduced version for MM-CIPN
patients was 14 [11–17]. A length-dependent sensory axonal,
large fibre neuropathy was evident from the nerve conduction
studies. This showed smaller amplitudes and longer latencies and
also impaired vibration and cooling thresholds on quantitative
sensory testing.
The subject-reported rating for pain intensity was recorded
before and after MRI scanning as shown in table 2. There were no
significant group differences (p.0.05) in median temperatures
applied to either the foot or thigh. There were no significant
differences (p.0.05) between pre-scanning and post-scanning pain
intensity rating in either healthy volunteers or MM-CIPN groups.
Chronic pain assessment
The total median CPAQ score in the MM group was 75. The
median sum score for activities engagement was 45 and that of
pain willingness was 31.
The total median catastrophisation score on the PCS was 11
(range 0–52) with the median scores (ranges) for magnification,
rumination and helplessness being 2.5 (0–12), 5 (0–16) and 4.5 (0–
24) respectively.
Table 3. Anatomical regions showing areas where statistical significant BOLD fMRI response to heat-pain stimuli were greater than
baseline temperature for Healthy Volunteers and myeloma patients with CIPN.
Healthy volunteers: Pain.Baseline
Region BA Talairach co-ordinates Peak t p (FWE-corr) Voxels*
R anterior cingulate 32 4 24 23 7.47 ,0.001 1643
L superior temporal gyrus 38 250 13 28 7.19 ,0.001 1491
L posterior cerebellar lobe - 230 267 220 6.56 0.002 2917
R inferior frontal gyrus 47 44 20 29 6.52 0.002 1151
R supramarginal gyrus 40 64 241 34 6.36 0.004 687
L superior temporal gyrus 42 260 230 18 6.13 0.007 709
L superior frontal gyrus 10 232 48 20 5.80 0.018 469
R middle frontal gyrus 46 42 44 24 5.73 0.02 390
R superior frontal gyrus 8 6 39 48 5.68 0.025 216
L postcentral gyrus 7 220 241 68 5.66 0.026 212
CIPN-myeloma patients: Pain.Baseline
Region BA Talairach co-ordinates Peak t p (FWE-corr) Voxels*
R superior temporal gyrus 22 56 4 0 8.10 ,0.001 1356
R supramarginal gyrus 40 62 241 35 7.65 ,0.001 735
L middle frontal gyrus 46 234 40 22 6.25 0.005 544
L area opercularis 44 254 2 12 6.07 0.008 2228
L posterior cerebellar lobe - 234 258 224 6.00 0.01 2535
*Voxels = number of voxels exceeding threshold p,0.001, uncorrected
doi:10.1371/journal.pone.0096474.t003
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Brain activation in response to heat-pain stimulation in
both healthy volunteers and MM-CIPN patients
Individual group analysis. Separate statistical parametric
activation maps were constructed for the MM-CIPN group and
the healthy volunteers group. Compared with baseline, heat-pain
stimulation evoked a BOLD response or ‘activation’ in both
healthy volunteers and patients with MM- CIPN (Table 3).
Comparison between groups. Patients with MM-CIPN
demonstrated significantly less activation in the right superior
frontal gyrus, close to the midline, than the healthy volunteer
group (Figure 1a; Brodmann area 8; Talairach co-ordinates: 6, 39,
48; peak t = 4.87; p = 0.03, FWE-corrected within the volume-of-
interest; 97 voxels exceeded height threshold p,0.001, uncorrect-
ed). Contrast estimates for pain stimulation at this focus, according
to group and stimulation site, are presented (Figure 1b).
Compared with healthy volunteers, MM-CIPN patients dem-
onstrated significantly greater activation in left precuneus
(Figure 2a; Brodmann area 31; Talairach co-ordinates: 218, 2
61, 27; peak t = 4.82; 244 voxels exceeded height threshold p,
0.001, uncorrected; p = 0.01, corrected for extent of activation).
This can be visualised in the plots for the contrast estimates for
pain stimulation at this focus, according to group and stimulation
site (Figure 2b).
Correlation of brain activation with the total neuropathy
score, reduced version
A linear regression analysis of fMRI signal response to heat-pain
stimulation at the foot (i.e., neuropathic site) within the MM-CIPN
patient group indicated significant correlation of BOLD response
with TNS-reduced version in the left operculo-insular cortex
(Figure 3a, 3b, Talairach co-ordinates: 258, 2 4; peak t = 8.02;
p = 0.03 FWE-corrected in the volume-of-interest for MM-CIPN
foot activation).
No significant correlations were identified in the MM-CIPN
patient group between BOLD response and CPAQ and/or the
PCS questionnaire scores.
Discussion
This is the first report of a fMRI study exploring central pain
processing in myeloma patients with chemotherapy-induced
peripheral neuropathy. In this initial study, a thermal stimulus
was applied to probe the subjects’ BOLD-fMRI response to acute
heat-pain. This type of stimulus was chosen since ‘burning pain
sensations’ often feature strongly in CIPN clinical symptomatol-
ogy. Our findings in patients who had this complex pathology
mirror and underpin the central changes in other neuropathic
Figure 1. CIPN-myeloma patients demonstrated a) hypo-activation of superior frontal gyrus during heat-pain stimulation,
compared with healthy volunteers. Functional imaging data are shown overlaid on both axial (z = 48 mm) and sagittal (x = 6 mm) slices through
a canonical single-subject T1-weighted image. For display purposes, the statistical threshold is p,0.001, uncorrected, at the voxel-level. b) Contrast
estimates and 90% CI at co-ordinate 6, 39, 48 for both healthy volunteer and CIPN-myeloma patient groups.
doi:10.1371/journal.pone.0096474.g001
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pain conditions reported in the literature. There was significant
activation of the precuneus in the MM-CIPN group during heat-
pain stimulation whilst there was significantly less response
observed in this area in healthy volunteers. The precuneus, which
lies on the posteromedial aspect of the parietal lobe, is thought to
play a role in conscious pain perception and is involved in a broad
range of higher order cognitive functions. Activation of the
posterior precuneus exhibits the strongest correlation with
successful retrieval of remembered episodes [31]. In MM-CIPN
patients, the enhanced precuneus response to painful stimulation
could imply that pain stimulates episodic pain memory retrieval.
This is consistent with the literature in normal individuals [32,33].
It has also been shown in patients with other chronic neuropathic
conditions [23,34–36].
In the MM-CIPN patients, there was a significant positive
correlation between increasing neuropathy score (TNS-reduced
version) and BOLD response in the operculo-insular cortex. This
region includes parts of the insula deep inside the lateral sulcus. It
also includes parts of the frontal and parietal lobes that cover the
insula, called the opercula. The operculum is known to play a part
in the cortical processing of painful stimuli [37]. There is evidence
to show that the intensity of activation of the operculo-insular
cortex correlates with perceived pain intensity in the human brain
[38].
Interestingly, in our cohort of MM-CIPN patients, no functional
anatomical response was identified in the superior frontal gyrus.
This could result from adaptation due to the chronic presence of
painful neuropathy of at least two years duration. Patients reported
high scores in the chronic pain acceptance questionnaire and low
scores in the pain catastrophizing questionnaire, which supports
the hypothesis that reduction in BOLD fMRI response to acute
heat-pain stimulation follows from long-term neuropathy-related
pathophysiology. Previous studies have highlighted deactivation of
the prefrontal cortex in response to pain in cluster headaches [39].
Repetitive transcranial magnetic stimulation has also been linked
to deactivation in capsaicin-induced pain [40]. Activation in the
right superior frontal gyrus has been previously reported in studies
applying painful stimuli to healthy volunteers and activation in this
area has been attributed to both the subjective experience of pain
and other general unpleasant experiences [41].
We identified regions that are known components of the brain’s
pain matrix, during painful stimulation in both healthy volunteers
and MM-CIPN patients. These functional areas are comparable to
those found in other disease groups [23,42–44].
Figure 2. CIPN-myeloma patients demonstrated a0 hyper-activation of precuneus during heat-pain stimulation, compared with
healthy volunteers. Functional imaging data are shown overlaid on both axial (z = 27 mm) and sagittal (x = 218 mm) slices through a canonical
single-subject T1-weighted image. For display purposes, the statistical threshold is p,0.001, uncorrected, at the voxel-level. b) Contrast estimates
and 90% CI at co-ordinate 218, 261, 27 for both healthy volunteer and CIPN-myeloma patient groups.
doi:10.1371/journal.pone.0096474.g002
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There are numerous factors that may influence the overall in-
vivo fMRI experiment [45]. In the current ‘box-car’ design, the
BOLD effect is based on changes in MR signal between functional
states, the source of which is assumed to be dominated by the net
haemodynamic change linked to localised differences in synaptic
and neuronal firing. It is not a direct measure of neuronal activity;
rather it is an indirect physiological response. The vascular
coupling is currently not fully understood, particularly in the
context of pathophysiology. One potential limitation of this study
was that the median age of the MM-CIPN group was greater than
that of the healthy volunteers (albeit similar, approximately 10
years). The reported influences of age on BOLD fMRI response
for non-pain-specific studies appear complex including overall
intracranial increases, increases in frontal regions and decreases in
the anterior regions, all with increasing age (a proposed posterior-
anterior shift with age reported between 22- year and 69- year old
normal volunteer groups) [46]. It must also be noted that
chemotherapeutic agents themselves may alter vascular function
and thus results should be interpreted in the light of these potential
modulatory factors. However, as effects caused by alterations in
cardiac output are likely to be systemic in nature and the group
age difference in this study being comparatively small, it is
assumed that potential effects between different intra-cranial
functional areas are secondary to the proposed neuropathic effects.
The significant correlation found with increasing neuropathic
severity supports this hypothesis. Additionally, in terms of group
response to pain-provoking stimulation, there were no significant
differences between median temperatures that were delivered and
their resultant pain ratings to either of the groups.
This was a cross-sectional screening study, with myeloma
patients having already developed neuropathy in the context of
receiving different anti-myeloma therapies. Some therapeutic
regimens included more than one possible CIPN-inducing agent.
Since no other known major risk factors for peripheral neuropathy
were identified, such as diabetes, human immunodeficiency virus
infection, chronic alcoholism, amyloidosis or renal failure, it would
seem that a chemo-therapeutic response was the major overall
causal factor linked to differences in both peripheral and central
nervous systems. In addition, although peripheral neuropathy is
seen at presentation in a small minority of patients with untreated
MM, in our study, neuropathic pain started only after having
received one of the anti-myeloma therapies described above. Most
drugs used as an anti-myeloma treatment cannot permeate the
blood–brain barrier [47]. The blood-nerve barrier protecting the
peripheral system does however appear to be sensitive to the
aforementioned agents. The PNS is thus more readily affected by
circulating drug neurotoxicity than CNS structures [48]. In the
light of this, the observed cerebral differences in BOLD response
to heat stimulation may result from changes in sensory input to the
brain or feedback circuitry via the spinal cord/brainstem.
Longitudinal data from patients with myeloma embarking on
chemotherapy would help to identify that CNS alterations do not
occur prior to peripheral changes and thus the primary effect-site
being the PNS. Such data would also help elucidate whether CNS
and PNS changes occur concurrently or whether alterations in
cerebral response follow a time lag suggestive of, for example,
brain function accustomisation. This preliminary study compared
a MM-CIPN cohort to findings in a healthy control group. Further
data obtained from disease-control groups, consisting of patients
with MM who have not developed symptoms or signs associated
with peripheral neuropathy and those in the acute phase who have
recently developed neuropathy, will add to our understanding of
neuropathic pathogenesis. Patients receiving long-term opioid
medication were not excluded and their medication was not
withdrawn, to facilitate involvement and to sample the patients in
their clinically relevant, chronic CIPN-state. It should be noted
Figure 3. a: CIPN-myeloma patients demonstrated activation in the operculo-insular cortex. This activation was during painful heat
stimulation, the degree of which correlated with TNS-reduced version. For display purposes, the statistical threshold is p,0.001, uncorrected, at the
voxel-level. b: Linear correlation between the TNS-reduced version and BOLD response within the operculo-insular cortex.
doi:10.1371/journal.pone.0096474.g003
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that future studies might reveal the potentially interesting
modulatory effects of this psychoactive agent.
In conclusion, our results indicate that fMRI is capable of
providing novel information with respect to the processing of pain
within the CNS in CIPN. The results show that painful stimuli
delivered to neuropathy-affected and symptom-free sites in our
patients with CIPN evoked differential activation of distinct
cortical regions. From this, we infer that the nociceptive system
may undergo plastic changes, which appear to reflect abnormal
central pain processing. Larger patient cohorts are needed to
ensure that the current findings represent those of CIPN in
general. Further identification and understanding of pathology-
specific CNS involvement may provide an objective, in-vivo-based
measure of pain experience and perception in patients with CIPN.
This may aid in diagnosis and may also provide adjunctive
information with which to steer targeting of novel pain-relieving
therapies.
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